Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1990 2
1998 1
2001 1
2002 2
2005 1
2006 1
2007 4
2008 4
2009 4
2010 2
2011 5
2012 4
2013 3
2014 5
2015 8
2016 16
2017 10
2018 8
2019 3
2020 5
2021 14
2022 20
2023 17
2024 11
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Results by year

Filters applied: . Clear all
Page 1
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer.
Wu YL, Dziadziuszko R, Ahn JS, Barlesi F, Nishio M, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Lu S, Wang Q, Ochi Lohmann T, Xu T, Cardona A, Ruf T, Noe J, Solomon BJ; ALINA Investigators. Wu YL, et al. N Engl J Med. 2024 Apr 11;390(14):1265-1276. doi: 10.1056/NEJMoa2310532. N Engl J Med. 2024. PMID: 38598794 Clinical Trial.
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.
Leighl NB, Akamatsu H, Lim SM, Cheng Y, Minchom AR, Marmarelis ME, Sanborn RE, Chih-Hsin Yang J, Liu B, John T, Massutí B, Spira AI, Lee SH, Wang J, Li J, Liu C, Novello S, Kondo M, Tamiya M, Korbenfeld E, Moskovitz M, Han JY, Alexander M, Joshi R, Felip E, Voon PJ, Danchaivijitr P, Hsu PC, Silva Melo Cruz FJ, Wehler T, Greillier L, Teixeira E, Nguyen D, Sabari JK, Qin A, Kowalski D, Şendur MAN, Xie J, Ghosh D, Alhadab A, Haddish-Berhane N, Clemens PL, Lorenzini P, Verheijen RB, Gamil M, Bauml JM, Baig M, Passaro A; PALOMA-3 Investigators. Leighl NB, et al. J Clin Oncol. 2024 Oct 20;42(30):3593-3605. doi: 10.1200/JCO.24.01001. Epub 2024 Jun 10. J Clin Oncol. 2024. PMID: 38857463 Free PMC article. Clinical Trial.
Giredestrant for Estrogen Receptor-Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study.
Martín M, Lim E, Chavez-MacGregor M, Bardia A, Wu J, Zhang Q, Nowecki Z, Cruz FM, Safin R, Kim SB, Schem C, Montero AJ, Khan S, Bandyopadhyay R, Moore HM, Shivhare M, Patre M, Martinalbo J, Roncoroni L, Pérez-Moreno PD, Sohn J; acelERA Breast Cancer Study Investigators. Martín M, et al. J Clin Oncol. 2024 Jun 20;42(18):2149-2160. doi: 10.1200/JCO.23.01500. Epub 2024 Mar 27. J Clin Oncol. 2024. PMID: 38537155 Free PMC article. Clinical Trial.
Evaluation of Patients with COVID-19 Followed Up in Intensive Care Units in the Second Year of the Pandemic: A Multicenter Point Prevalence Study.
Güngör S, Ediboğlu Ö, Yazıcıoğlu Moçin Ö, Adıgüzel N, Tuncay E, Ekiz İşcanlı İG, Er B, Karakurt Z, Turan S, Kosovalı BD, Mutlu NM, Kayar D, Gökbulut Bektaş Ş, Uysal E, Seğmen F, Alp G, Erdem D, Has Selmi N, Güven P, Özçelik Z, Ocakcıoğlu M, Yazıcı Özgür C, Yılmaz R, Bilgi Özel D, Cebeci H, Güler B, Cansever C, Çakırca M, İnceöz H, Solmaz İ, Özkan Sipahioğlu F, Aydın EM, Dayanır H, Öner SF, Karatepe U, Özen S, Boran M, Ergül DF, Kasapoğlu US, Delen LA, Toy E, Altun K, Albayrak T, Yanal H, Zaim G, Yarar V, Kılınç G, Deniz M, Özdemir E, Soylu VG, Yılmaz A, Saygılı SM, Öztürk EK, Ergan B, Eyüpoğlu S, Şahin Y, Yüksel B, Bulut A, Sarıtaş A, Yeniay H, Genç M, Kargın F, Özcan O, Karakoç E, Karaca Ü, Sözütek D, Sarı S, Şenoğlu N, Aygün H, Yiğit AC, Kavruk N, Uzan ÇA, Bıçakcıoğlu M, Solak S, Kutbay Özçelik H, Uluç K, Yıldırım İ, Arar MC, Demirel İ, Küver SU, Özgür ES, Aydın K, Erdal Dönmez G, Aygencel G, Esmaoğlu A, Sebil Aydın B, Tokur ME, Korkmaz Ekren P, Aydemir Y, Çakır Güney B, Erdil ÖY, Tünay A, Bahadır T, Uçkun S, Kocaoğlu N, Pınar HU, Kutluer Karaca N, Gültekin H, Ayvat P, Belin Özer A, Eroğlu A, Kuyrukluyıldız U, Baytar Ç, Ayoğlu H, Mızrakçı S, Metin H, Zanbak Mutlu ÖP, Yılm… See abstract for full author list ➔ Güngör S, et al. Among authors: erdem d. Thorac Res Pract. 2023 Nov 23;25(1):11-6. doi: 10.5152/ThoracResPract.2023.23024. Online ahead of print. Thorac Res Pract. 2023. PMID: 37994835 Free PMC article.
Response to the letter to the editor.
Guner R, Hasanoglu I, Kayaaslan B, Aypak A, Akinci E, Bodur H, Eser F, Kaya Kalem A, Kucuksahin O, Ates I, Bastug A, Tezer Tekce Y, Bilgic Z, Gursoy FM, Akca HN, Izdes S, Erdem D, Asfuroglu E, Hezer H, Kilic H, Civak M, Aydogan S, Buzgan T. Guner R, et al. Among authors: erdem d. J Infect Public Health. 2022 Jan;15(1):65-67. doi: 10.1016/j.jiph.2021.12.007. Epub 2021 Dec 11. J Infect Public Health. 2022. PMID: 34915424 Free PMC article. No abstract available.
Real-world outcomes of pazopanib in metastatic soft tissue sarcoma: a retrospective Turkish oncology group (TOG) study.
Bilici A, Koca S, Karaagac M, Aydin SG, Eraslan E, Kaplan MA, Ocak B, Goksu SS, Paydas S, Akgul F, Derin S, Ergun Y, Yekeduz E, Erol C, Ozyukseler DT, Demiray AG, Karaca M, Guc ZG, Menekse S, Cinkir HY, Gumusay O, Sakin A, Ozkul O, Demir H, Erdem D, Besiroglu M, Unal OU, Acar R, Koral L, Sahin S, Sakalar T, Bahceci A, Ozveren A, Gunaydin UM, Seker MM, Sunar V, Dal P, Artac M, Turhal S. Bilici A, et al. Among authors: erdem d. J Cancer Res Clin Oncol. 2023 Sep;149(11):8243-8253. doi: 10.1007/s00432-023-04766-3. Epub 2023 Apr 17. J Cancer Res Clin Oncol. 2023. PMID: 37067546
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy.
Karacin C, Oksuzoglu B, Demirci A, Keskinkılıç M, Baytemür NK, Yılmaz F, Selvi O, Erdem D, Avşar E, Paksoy N, Demir N, Göksu SS, Türker S, Bayram E, Çelebi A, Yılmaz H, Kuzu ÖF, Kahraman S, Gökmen İ, Sakin A, Alkan A, Nayır E, Uğraklı M, Acar Ö, Ertürk İ, Demir H, Aslan F, Sönmez Ö, Korkmaz T, Celayir ÖM, Karadağ İ, Kayıkçıoğlu E, Şakalar T, Öktem İN, Eren T, Erul E, Mocan EE, Kalkan Z, Yıldırım N, Ergün Y, Akagündüz B, Karakaya S, Kut E, Teker F, Demirel BÇ, Karaboyun K, Almuradova E, Ünal OÜ, Oyman A, Işık D, Okutur K, Öztosun B, Gülbağcı BB, Kalender ME, Şahin E, Seyyar M, Özdemir Ö, Selçukbiricik F, Kanıtez M, Dede İ, Gümüş M, Gökmen E, Yaren A, Menekşe S, Ebinç S, Aksoy S, İmamoğlu Gİ, Altınbaş M, Çetin B, Uluç BO, Er Ö, Karadurmuş N, Erdoğan AP, Artaç M, Tanrıverdi Ö, Çiçin İ, Şendur MAN, Oktay E, Bayoğlu İV, Paydaş S, Aydıner A, Salim DK, Geredeli Ç, Yavuzşen T, Doğan M, Hacıbekiroğlu İ. Karacin C, et al. Among authors: erdem d. BMC Cancer. 2023 Feb 10;23(1):136. doi: 10.1186/s12885-023-10609-8. BMC Cancer. 2023. PMID: 36765293 Free PMC article.
Real-World Efficacy and Safety of First-Line Nivolumab Plus Chemotherapy in Patients with Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: A Nationwide Observational Turkish Oncology Group (TOG) Study.
Kutlu Y, Dae SA, Yilmaz F, Erdem D, Sendur MAN, Akbas S, Senocak Tasci E, Bas O, Dane F, Sakin A, Kaya AO, Aykan MB, Ergun Y, Biter S, Disel U, Korkmaz M, Selcukbiricik F, Kose F, Olmez OF, Bilici A, Demir G, Yalcin S. Kutlu Y, et al. Among authors: erdem d. Cancers (Basel). 2024 Jun 18;16(12):2251. doi: 10.3390/cancers16122251. Cancers (Basel). 2024. PMID: 38927957 Free PMC article.
123 results